<DOC>
	<DOCNO>NCT02842242</DOCNO>
	<brief_summary>The purpose phase 2 open-label pilot study evaluate efficacy , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) , safety , tolerability MYK-461 subject symptomatic HCM LVOT obstruction age 18-70 year .</brief_summary>
	<brief_title>A Phase 2 Open-label Pilot Study Evaluating MYK-461 Subjects With Symptomatic Hypertrophic Cardiomyopathy Left Ventricular Outflow Tract Obstruction</brief_title>
	<detailed_description />
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomyopathy , Hypertrophic</mesh_term>
	<criteria>Key Diagnosed HCM ( hypertrophy nondilated left ventricle absence systemic know cause ) , LV wall thickness ≥ 15 mm time initial diagnosis ≥ 13 mm positive family history HCM . Age 1870 BMI 1837kg/m2 Documented LVEF ≥ 55 % Screening visit determine investigator investigational site 's echocardiography laboratory . Resting LVOT gradient ≥ 30 mg Hg postexercise peak LVOT gradient ≥ 50 mm Hg NYHA functional class II high Key History sustain ventricular tachyarrhythmia . History syncope exercise within past 6 month . Active infection . Persistent atrial fibrillation atrial fibrillation Screening . Has QTc Fridericia ( QTcF ) &gt; 500 m , ECG abnormality consider investigator pose risk subject safety ( e.g . second degree atrioventricular block type II ) . Aortic stenosis fix subaortic obstruction . History LV systolic dysfunction ( LVEF &lt; 45 % ) time clinical course . History coronary artery disease . History evidence clinically significant disorder , condition , disease , opinion investigator MyoKardia physician , would pose risk subject safety interfere study evaluation , procedure , completion . Ongoing therapy beta blocker , calcium channel blocker , disopyramide . Subjects medication , opinion investigator , safely withdrawn eligible long medication discontinue least 14 day prior Screening visit . Prior treatment cardiotoxic agent doxorubicin similar , current treatment antiarrhythmic drug negative inotropic activity , e.g . flecainide propafenone .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>